Research Topics
| Diane WardenSummaryAffiliation: University of Texas Southwestern Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuseDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, USA
Contemp Clin Trials 33:29-37. 2012..It may be helpful to researchers who are developing criteria and methods for site selection for specific clinical trials...
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youthDiane Warden
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, USA
Addict Behav 37:1046-53. 2012..If youth at risk for attrition can be identified at treatment entry or early in treatment, they can be targeted for interventions to help retain them in treatment...- Major depression and treatment response in adolescents with ADHD and substance use disorderDiane Warden
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, United States
Drug Alcohol Depend 120:214-9. 2012.... 
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D reportDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9086, USA
Am J Psychiatry 164:1189-97. 2007..The purpose of this study was to identify the pretreatment predictors of attrition during acute treatment with citalopram in a large, "real world" clinical trial...- Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study reportDiane Warden
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
J Clin Psychopharmacol 30:259-66. 2010..Neither global ratings nor specific adverse effects at week 2 were related to patient attrition during SSRI treatment. Other factors seem to contribute to patient decisions about continuing with treatment... - Identifying risk for attrition during treatment for depressionDiane Warden
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, USA
Psychother Psychosom 78:372-9. 2009..Understanding patients' ambivalence about treatment persistence may be useful in tailoring retention interventions for individual patients with major depressive disorder... - Predictors of attrition during one year of depression treatment: a roadmap to personalized interventionDiane Warden
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, USA
J Psychiatr Pract 15:113-24. 2009..To assist in tailoring the delivery of interventions to specific patients to reduce attrition, this study reports the incidence, timing, and predictors of attrition from outpatient treatment in public mental health clinics... - Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disordersD Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
Psychol Med 40:955-65. 2010..No measure of patients' anticipated benefits of treatment on domains of everyday functioning has previously been available... - The STAR*D Project results: a comprehensive review of findingsDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390 9086, USA
Curr Psychiatry Rep 9:449-59. 2007..These results highlight the prevalence of treatment-resistant depression and suggest potential benefit for using more vigorous treatments in the earlier steps... - What predicts attrition in second step medication treatments for depression?: a STAR*D ReportDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
Int J Neuropsychopharmacol 12:459-73. 2009..Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes... - Income and attrition in the treatment of depression: a STAR*D reportDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9086, USA
Depress Anxiety 26:622-33. 2009..This report assessed whether attrition rates and predictors of attrition differed among depressed outpatients with different income levels... - Quality improvement methods as applied to a multicenter effectiveness trial--STAR*DDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX, USA
Contemp Clin Trials 26:95-112. 2005..This paper describes the background, rationale, development, and potential utility of implementing a quality improvement system to improve the performance and efficiency of the trial... - Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysisBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
Ann Fam Med 5:126-34. 2007.... - Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D reportMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, 3811 OHara St, Pittsburgh, PA 15213 2593, and Massachusetts General Hospital, USA
Am J Psychiatry 164:739-52. 2007..Cognitive therapy was compared with medication augmentation and switch strategies... - Acceptability of second-step treatments to depressed outpatients: a STAR*D reportStephen R Wisniewski
Department of Psychiatry, Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, and Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA
Am J Psychiatry 164:753-60. 2007..This study sought to identify factors that affect patients' willingness to accept different second-step treatment approaches... - Medication augmentation after the failure of SSRIs for depressionMadhukar H Trivedi
Mood Disorder Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
N Engl J Med 354:1243-52. 2006..Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach... - Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment featuresA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390, USA
Arch Gen Psychiatry 65:870-80. 2008..Little is known about selecting among second-step medications for major depressive disorder after intolerance or lack of remission with an initial selective serotonin reuptake inhibitor... - Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcomeRobert H Howland
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213, United States
Drug Alcohol Depend 99:248-60. 2009.... - Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
Am J Psychiatry 163:1905-17. 2006..This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial... - Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D studySidney Zisook
Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, San Diego, California, USA
J Affect Disord 117:63-73. 2009..The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI... - Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceMadhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center, Exchange Park Express, American General Tower, 6363 Forest Park Rd, Suite 1300, Dallas, TX 75390 9119, USA
Am J Psychiatry 163:28-40. 2006.... - Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED reportWilliam V Bobo
Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, USA
J Affect Disord 133:467-76. 2011..The clinical effects of antidepressant combinations vs. monotherapy as initial treatment for major depression with melancholic features (MDD-MF) are unknown... - Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D reportMadhukar H Trivedi
Department of Psychiatry, University of Texas UT Southwestern Medical Center, Dallas 75390 9119, and the Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA
J Clin Psychiatry 67:185-95. 2006..The aim of this study was to examine sociodemographic and clinical correlates of HRQOL in a large cohort of outpatients with MDD... - Assessing anxious features in depressed outpatientsShawn M McClintock
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 8898, USA
Int J Methods Psychiatr Res 20:e69-82. 2011..Both the HRSD(ANX) and IDS-C(ANX) subscales have acceptable psychometric properties and can be used to identify anxious features for clinical or research purposes... - What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depressionBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Psychiatr Serv 60:1439-45. 2009..STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed... - Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based careMadhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
Neuropsychopharmacology 32:2479-89. 2007..This approach signals a paradigm shift toward the use of measurement-based clinical decisions, both at the point of care and following each visit, to deliver optimal pharmacotherapy for depression... - Health-related quality of life in depression: a STAR*D reportElla J Daly
Department of Psychiatry, University of Texas Southwestern Medical School at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, USA
Ann Clin Psychiatry 22:43-55. 2010..This report examined the psychological, physical, and social domains in a large sample of outpatients who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial... - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depressionA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
N Engl J Med 354:1231-42. 2006..After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another... - Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal riskMadhukar H Trivedi
Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
J Clin Psychiatry 72:757-64. 2011..This report evaluates the psychometric properties of a brief self- and clinician-rated measure of factors related to the risk of suicide attempt or completion... - Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*DWilliam R Yates
Department of Psychiatry, University of Oklahoma College of Medicine, Tulsa, OK 74135, USA
Gen Hosp Psychiatry 26:421-9. 2004..A significant percentage of patients with major depressive disorder (MDD) suffer from concurrent general medical conditions (GMCs)... - A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trialBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7160, USA
Gen Hosp Psychiatry 27:87-96. 2005..The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (http://www.star-d.org) provides a unique opportunity to provide this comparison for patients with a major depressive disorder (MDD) requiring treatment... - Comorbid psychiatric disorders in depressed outpatients: demographic and clinical featuresA John Rush
Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 9086, USA
J Affect Disord 87:43-55. 2005..This study evaluated the clinical and sociodemographic features associated with various degrees of concurrent comorbidity in adult outpatients with nonpsychotic major depressive disorder (MDD)... - Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trialMadhukar H Trivedi
The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9119, USA
Trials 12:206. 2011..CLINICAL TRIALS REGISTRY: ClinicalTrials.gov, NCT01141608 http://clinicaltrials.gov/ct2/show/NCT01141608?term=Stimulant+Reduction+Intervention+using+Dosed+Exercise&rank=1... - Effects of race and ethnicity on depression treatment outcomes: the CO-MED trialIra M Lesser
Department of Psychiatry, Harbor UCLA Medical Center, Torrance, CA, USA
Psychiatr Serv 62:1167-79. 2011.... - STAR*D: revising conventional wisdomA John Rush
Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA
CNS Drugs 23:627-47. 2009..Although switch and augmentation strategies could not be directly compared due to the equipoise stratified randomized design, the higher remission rates at step 2 with medication augmentation are intriguing and merit further study... - Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidalityMadhukar H Trivedi
Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9119, USA
J Clin Psychiatry 72:765-74. 2011.... - Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medicationShawn M McClintock
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 8898, USA
J Clin Psychopharmacol 31:180-6. 2011..Individualized treatments are warranted to specifically address each patient's residual depressive symptoms... - Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatientsMadhukar H Trivedi
Professor of Psychiatry, Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Can J Psychiatry 58:113-22. 2013..Clinical Trial Registration Number: Sequenced Treatment Alternatives to Relieve Depression, NCT00021528... - Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysisWilliam R Yates
Department of Psychiatry, University of Oklahoma College of Medicine, Tulsa, OK, USA
Prim Care Companion J Clin Psychiatry 9:7-15. 2007..This association has implications for diagnosis and clinical care... - The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measuresThomas J Carmody
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd Dallas, TX 75390 9086, United States
Eur Neuropsychopharmacol 16:601-11. 2006..An HRSD(17) of 7 corresponded to an 8 or 9 on the MADRS and 4 on the HRSD(6). The MADRS would be superior to the HRSD(17) in the conduct of clinical trials... - Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037)Madhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 75390 9119, USA
Am J Drug Alcohol Abuse 37:339-49. 2011..Abstinence is the most desirable treatment outcome although a wide variety of other endpoints have been used... - The quick inventory of depressive symptomatology (clinician and self-report versions) in patients with bipolar disorderIra H Bernstein
Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390 9066, USA
CNS Spectr 15:367-73. 2010..This article examines these measures in a second sample of 141 outpatients with bipolar disorder in different phases of the illness... - Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D reportMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
Am J Psychiatry 165:342-51. 2008..The authors conducted a secondary data analysis to compare antidepressant treatment outcomes for patients with anxious and nonanxious major depression in Levels 1 and 2 of the STAR*D study... - Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) studyAndrew A Nierenberg
Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 01224, USA
J Affect Disord 108:129-34. 2008..It is unknown, however, whether patients with a family member who committed suicide differ from those without such a history... - Electronic source materials in clinical research: acceptability and validity of symptom self-rating in major depressive disorderIan A Cook
UCLA Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, 760 Westwood Plaza, Los Angeles, CA 90024 1759, USA
J Psychiatr Res 41:737-43. 2007..We then examined ease of use, the equivalence of responses between paper and electronic methods, and the acceptability of the tablet PC for this clinical population... - Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trialSteven D Hollon
Department of Psychology, Vanderbilt University, 306 Wilson Hall, Nashville, TN 37203, United States
J Psychiatr Res 40:59-69. 2006..Recurrent depression predicts risk for subsequent episodes, but it is unclear how it relates to demographic features, course of illness, and clinical presentation... - Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D reportPatrick J McGrath
Depression Evaluation Service, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
Am J Psychiatry 163:1531-41; quiz 1666. 2006.... - A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D reportAndrew A Nierenberg
Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
Am J Psychiatry 163:1519-30; quiz 1665. 2006..This study compared the effectiveness of lithium versus triiodothyronine (T(3)) augmentation as a third-step treatment for patients with major depressive disorder... - Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohortLori L Davis
VA Medical Center, Tuscaloosa, AL 35404, USA
Am J Addict 15:278-85. 2006..048 to <0.0001). They were also less likely to be Hispanic and endorse general medical comorbidities (p = 0.006 and 0.002, respectively)... - A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D reportMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Bulfinch 351, 55 Fruit St, Boston, MA 02114, USA
Am J Psychiatry 163:1161-72. 2006.... - Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) projectStephen R Wisniewski
Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, PA 15261, USA
Clin Trials 1:387-98. 2004.... - Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D reportWilliam S Gilmer
Asher Center for the Study and Treatment of Depressive Disorders, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
J Clin Psychiatry 69:1246-56. 2008....